Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-30
2007-01-30
Tsang, Cecilia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000, C544S127000, C514S300000, C514S235500, C546S113000
Reexamination Certificate
active
10399051
ABSTRACT:
The invention relates to new 7-azaindoles, their use as inhibitors of phosphodiesterase 4 and to methods for their synthesis.
REFERENCES:
patent: 5023265 (1991-06-01), Scherlock et al.
patent: 5464861 (1995-11-01), Dobrusin et al.
patent: 5811432 (1998-09-01), Marfat et al.
patent: 1 141 949 (1969-02-01), None
patent: 09221423 (1987-08-01), None
patent: 06247966 (1994-09-01), None
patent: 09169665 (1997-06-01), None
patent: 10 120681 (1998-05-01), None
patent: WO-91/09598 (1991-07-01), None
patent: WO-94/02465 (1994-02-01), None
patent: WO-94/03427 (1994-02-01), None
patent: WO-95/28926 (1995-11-01), None
patent: WO-96/11929 (1996-04-01), None
patent: WO-96 11929 (1996-04-01), None
patent: WO-96/31476 (1996-10-01), None
Burnouf C. Annual Reports in Medicinal Chemistry, 1998, Academic Press, Chapter 10, pp. 91-109.
Giembycz, Mark A., “Cilomilast: a second generation phosphoiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease”, Expert Opinion Investig. Drugs (2002) 10(7):1361-1379.
Patent Abstracts of Japan, JP 04021681 dated Jan. 24, 1992.
Tyrosine Kinase Inhibitors, , Rewcastle, et al.. J. Med. Chem. 1994.
Corticotropin-Releasing Hormone . . . Studies, Hodge, et al. J. Med. Chem. 1999.
New 5-HT3(Serotonin-3) Receptor, IV Synthesis and Structure., Kato, et al. Chem. Pharm. Bull. 43, (8) 1995.
Palfreyman, et al. “Phosphodiesterase Type IV Inhibitors” Progress in Medicinal Chemistry- vol. 33 (1996).
Miyamoto, et al., “Reduction of Bone Loss by Denbufylline, an Inhibitor of Phosphodiesterase 4”, Biochemical Pharmacology, vol. 54 (1997).
Hanifin, et al. “Monocyte Phosphodiesterase Abnormalities and Dysregulation of Lymphocyte Function in Atopic Dermatitis”, The Society for Investigative Dermatology, Inc. vol. 105. (1995).
Cavalla, et al., “Phosphodiesterase IV Inhibitors: Structural Diversity and Therapeutic Potential in Asthma”, Current Medicinal Chemistry (1995).
Palfreyman, “Phosphodiesterase type IV Inhibitors as anti-inflammatory agents”, Drugs of the Future (1995).
Karlsson, et al. “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Phosphodiesterase 4 inhibitors for the treatment of asthma”, (1997).
Palacios, et al., “Second Messenger Systems as Targets for New Therapeutic Agents: Focus on Selective Phosphodiesterase Inhibitors”, II Farmaco, 50 (1995).
Egerland Ute
Höfgen Norbert
Kronbach Thomas
Kuss Hildegard
Marx Degenhard
Elbion AG
Fulbright & Jaworski L.L.P.
Hoffman Lexington A.
Tsang Cecilia
LandOfFree
7-azaindoles, use thereof as phosphodiesterase 4 inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823694